Influence of timing of seasonal influenza vaccination on effectiveness and cost-effectiveness in pregnancy - 19/08/11
, Derek A. Misurski, PhD, RPh c, Geeta K. Swamy, MD b
Reprints: Evan R. Myers, MD, MPHRésumé |
The purpose of this review was to estimate the impact of timing of seasonal influenza vaccination during pregnancy on health and economic outcomes. Cost-effectiveness analysis with a dynamic model of the US population of pregnant women and infants who were <6 months incorporated seasonal variation in influenza incidence. Compared with no vaccination, seasonal influenza vaccination in pregnancy costs $70,089 per quality-adjusted life year. Most of the benefit for infants was limited to those whose mothers were vaccinated within the first 4 weeks of vaccine availability. Once all women who were pregnant at the time of vaccine availability were vaccinated, vaccination of newly pregnant women had benefits for mothers but not infants. Delay of vaccination beyond November reduced both effectiveness and cost-effectiveness. The greatest population benefit from seasonal influenza vaccination in pregnancy was realized if pregnant women were vaccinated as soon as possible after trivalent inactivated influenza vaccine became available. Efforts to increase vaccine rates should be concentrated early in the influenza season.
Le texte complet de cet article est disponible en PDF.Key words : cost-effectiveness, seasonal influenza, simulation, vaccination
Plan
| Conflict of Interest: Dr Myers reported serving as a member of the GlaxoSmithKline (GSK) scientific advisory board for influenza vaccination among elderly adults, has served as a safety monitor for NIH-sponsored trials of influenza vaccine in pregnancy, and has received research funding and served as a consultant for Merck regarding human papillomavirus vaccination. Dr Misurski is an employee of GSK, and owns GSK stock. Dr Swamy reported serving on the GSK Speaker's Bureau for Seasonal Influenza Vaccine and as a member of the GSK scientific advisory board for Tdap (tetanus, diphtheria, acellular pertussis) vaccine. She has served as an investigator of NIH and CDC-sponsored studies of influenza vaccination in pregnancy. |
|
| Supported by an unrestricted grant to Duke University from GlaxoSmithKline, Inc. |
|
| Publication of this article was supported by the Centers for Disease Control and Prevention and the Association of Maternal and Child Health Programs. |
Vol 204 - N° 6S
P. S128-S140 - juin 2011 Retour au numéro
Article précédent
- Predictors of H1N1 vaccination in pregnancy
- Dmitry Fridman, Eric Steinberg, Erum Azhar, Jeremy Weedon, Tracey E. Wilson, Howard Minkoff
- Impact of maternal immunization on influenza hospitalizations in infants
- Katherine A. Poehling, Peter G. Szilagyi, Mary A. Staat, Beverly M. Snively, Daniel C. Payne, Carolyn B. Bridges, Susan Y. Chu, Laney S. Light, Mila M. Prill, Lyn Finelli, Marie R. Griffin, Kathryn M. Edwards, New Vaccine Surveillance Network
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?